Sunday, May 17, 2026 9:46:35 AM
While a form 483 isn’t good it doesn’t necessarily mean no fda approval….not an official kiss of death…🤞
As far as unisource goes….yes great partnership….I like it…
The "Unicycive and UniSource partnership" refers to a dedicated patient support program established by Unicycive Therapeutics (NASDAQ: UNCY) for individuals managing chronic kidney disease.
UniSource is a branded reimbursement and access support hub operated by Unicycive Therapeutics. It serves as a centralized resource rather than a traditional corporate or joint business partnership.
Key services provided by UniSource include:
Benefits Verification: Helping patients and healthcare providers quickly determine insurance coverage.
Prior Authorization Support: Assisting with the necessary paperwork to secure drug approvals.
Financial Assistance Programs: Navigating co-pay support and other affordability options for eligible patients.
Unicycive established the UniSource hub to support the commercial rollout of its lead investigational drug, oxylanthanum carbonate (OLC), which treats hyperphosphatemia in dialysis patients.
👍👏
As far as unisource goes….yes great partnership….I like it…
The "Unicycive and UniSource partnership" refers to a dedicated patient support program established by Unicycive Therapeutics (NASDAQ: UNCY) for individuals managing chronic kidney disease.
UniSource is a branded reimbursement and access support hub operated by Unicycive Therapeutics. It serves as a centralized resource rather than a traditional corporate or joint business partnership.
Key services provided by UniSource include:
Benefits Verification: Helping patients and healthcare providers quickly determine insurance coverage.
Prior Authorization Support: Assisting with the necessary paperwork to secure drug approvals.
Financial Assistance Programs: Navigating co-pay support and other affordability options for eligible patients.
Unicycive established the UniSource hub to support the commercial rollout of its lead investigational drug, oxylanthanum carbonate (OLC), which treats hyperphosphatemia in dialysis patients.
👍👏
Recent UNCY News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2026 08:30:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:51:50 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/12/2026 10:30:46 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/30/2026 11:04:02 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/30/2026 11:02:10 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/30/2026 11:00:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
